Financial News

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

New Cancer Research Could Be a Massive Game Changer for Ozempic and Mounjaro

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7% and the actively trad

Here are the companies making headlines in midday trading.

The Investment Committee debate the latest Calls of the Day.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly (LLY) will acquire three vaccine developers in all-cash deals with a combined value of up

US equity futures were edging higher pre-bell Tuesday as traders monitored the US-Iran situation for

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins

In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.

Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 […]

Eli Lilly shares were little changed after the pharmaceutical giant reported promising early data for an experimental heart-disease gene therapy. The pharmaceutical giant said Monday that a single infusion of its gene therapy candidate, Verve-102, reduced PCSK9 protein levels by up to 88% and lowered LDL cholesterol by as much as 62%. PCSK9 is a protein that regulates cholesterol levels in the bloodstream.

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

CNBC’s Annika Kim Constantino reports on Eli Lilly as the pharma giant announced plans to acquire three companies for nearly $4 billion in cash.

Walmart's recent run of outperformance could be coming to an end.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in differentiated technology platforms to address significant health problems.

Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved productsSEATTLE, May 26, 2026 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive agreement to be acquired by Lilly. Curevo’s lead product candidate is amezosvatein, an a

Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly.

SCHLIEREN (ZURICH), Switzerland, May 26, 2026--LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly.

(Bloomberg) -- US equity futures gained and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on Uranium

CNBC’s Jim Cramer delivers his daily Mad Dash.

These players are seeing exciting results in clinical trials.

These are some of the stocks posting the largest moves in early trading.